Form 8-K Edwards Lifesciences For: Oct 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
October 28, 2024 8:19 AM EDTBernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.
The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More
BTIG Reiterates Neutral Rating on Edwards Lifesciences (EW)
October 25, 2024 5:22 AM EDTBTIG analyst Marie Thibault reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW).
The analyst comments "There were a few moving parts with this quarter's print following the sale of the Critical Care business in September as well as the discontinuation of a small non-core product group in the Surgical Structural Heart business that generates ~$60-70M in annual sales. Excluding these items, EW grew revenue by 9.6% y/y CC in Q3 and reported adj. EPS of $0.67. Total TAVR sales of $1.023B were $13M above consensus of $1.010B (+6.5% y/y rep., +7.2% CC).... More
